npj Parkinsons Disease

Article	Citations
Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation	306
Current and projected future economic burden of Parkinson’s disease in the U.S.	253
Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens	132
COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside	109
Genetic predispositions of Parkinson’s disease revealed in patient-derived brain cells	82
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease	69
Sex specific cognitive differences in Parkinson disease	65
Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life	61
Dynamic control of the dopamine transporter in neurotransmission and homeostasis	56
The impact of COVID-19 and social distancing on people with Parkinson’s disease: a survey study	54
How COVID-19 will boost remote exercise-based treatment in Parkinson’s disease: a narrative review	53
Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management	52
Toward therapeutic electrophysiology: beta-band suppression as a biomarker in chronic local field potential recordings	46
Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes	45
Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity	44
Is LRRK2 the missing link between inflammatory bowel disease and Parkinson’s disease?	44
Incidence of Parkinson disease in North America	44
Genetic and environmental factors in Alzheimer’s and Parkinson’s diseases and promising therapeutic intervention via fecal microbiota transplantation	43
Multi-modality machine learning predicting Parkinson’s disease	42
Subthalamic and pallidal deep brain stimulation for Parkinson’s disease—meta-analysis of outcomes	41
Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease	41
A systematic review on exercise and training-based interventions for freezing of gait in Parkinson’s disease	41
Diagnostic value of skin RT-QuIC in Parkinson’s disease: a two-laboratory study	40
Timing variability and midfrontal ~4 Hz rhythms correlate with cognition in Parkinson’s disease	39
A postmortem study suggests a revision of the dual-hit hypothesis of Parkinson’s disease	39

Probiotics synergized with conventional regimen in managing Parkinson’s disease	38
Neuroimaging evidence of glymphatic system dysfunction in possible REM sleep behavior disorder and Parkinson’s disease	37
Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies	37
Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology	35
Plasma-borne indicators of inflammasome activity in Parkinson’s disease patients	34
Stress and mindfulness in Parkinson’s disease – a survey in 5000 patients	33
Eight-hours conventional versus adaptive deep brain stimulation of the subthalamic nucleus in Parkinson’s disease	32
Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis	31
Oleh Hornykiewicz, a giant in the understanding and treatment of Parkinson disease	31
Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson’s disease	30
The role of brain perivascular space burden in early-stage Parkinson’s disease	30
Parkinson’s disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI	30
Reduced astrocytic reactivity in human brains and midbrain organoids with PRKN mutations	29
Cognitive function in people with and without freezing of gait in Parkinson’s disease	29
Mechanisms of peripheral levodopa resistance in Parkinson’s disease	28
A transcriptome-wide association study identifies susceptibility genes for Parkinson’s disease	28
Diurnal modulation of subthalamic beta oscillatory power in Parkinson’s disease patients during deep brain stimulation	28
Long-term effect of apomorphine infusion in advanced Parkinson’s disease: a real-life study	27
Rheumatoid arthritis decreases risk for Parkinson’s disease: a Mendelian randomization study	27
Astrocytic atrophy as a pathological feature of Parkinson’s disease with LRRK2 mutation	27
Early constipation predicts faster dementia onset in Parkinson’s disease	27
Fine mapping of the HLA locus in Parkinson’s disease in Europeans	27
Sex-based differences in the activation of peripheral blood monocytes in early Parkinson disease	26
Plasma branched-chain and aromatic amino acids correlate with the gut microbiota and severity of Parkinson’s disease	25
Lewy body disease or diseases with Lewy bodies?	25
A nationwide study of the incidence, prevalence and mortality of Parkinson’s disease in the Norwegian population	25
Specific immune status in Parkinson’s disease at different ages of onset	25
A real-world study of wearable sensors in Parkinson’s disease	25
Mining genetic and transcriptomic data using machine learning approaches in Parkinson’s disease	25
Cofilin 1 promotes the pathogenicity and transmission of pathological α-synuclein in mouse models of Parkinson’s disease	25
Mining imaging and clinical data with machine learning approaches for the diagnosis and early detection of Parkinson’s disease	25
Effects of the agility boot camp with cognitive challenge (ABC-C) exercise program for Parkinson’s disease	24
Acquired dysregulation of dopamine homeostasis reproduces features of Parkinson’s disease	24
Repetitive transcranial magnetic stimulation improves Parkinson’s freezing of gait via normalizing brain connectivity	24
Multimodal phenotypic axes of Parkinson’s disease	23
Detection of SARS-CoV-2 viral proteins and genomic sequences in human brainstem nuclei	23
Multivariate prediction of dementia in Parkinson’s disease	23
Multiple comorbid sleep disorders adversely affect quality of life in Parkinson’s disease patients	23
Parkinson’s disease clinical milestones and mortality	23
Speech-based characterization of dopamine replacement therapy in people with Parkinson’s disease	22
α-Synuclein aggregation in the olfactory bulb induces olfactory deficits by perturbing granule cells and granular–mitral synaptic transmission	22
Subthalamic beta bursts correlate with dopamine-dependent motor symptoms in 106 Parkinson’s patients	22
Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease	22
Astrogliosis and sexually dimorphic neurodegeneration and microgliosis in the olfactory bulb in Parkinson’s disease	22
Prognostic biomarkers of Parkinson’s disease in the Spanish EPIC cohort: a multiplatform metabolomics approach	22
Synucleinopathy-associated pathogenesis in Parkinson’s disease and the potential for brain-derived neurotrophic factor	22
RETRACTED ARTICLE: Non-invasive vagus nerve stimulation improves clinical and molecular biomarkers of Parkinson’s disease in patients with freezing of gait	21
Gender gap in deep brain stimulation for Parkinson’s disease	21
Diffusion along perivascular spaces as marker for impairment of glymphatic system in Parkinson’s disease	20
Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures	20

Reduced synaptic activity and dysregulated extracellular matrix pathways in midbrain neurons from Parkinson’s disease patients	20
A blinded, controlled trial of objective measurement in Parkinson’s disease	20
Protection from α-Synuclein induced dopaminergic neurodegeneration by overexpression of the mitochondrial import receptor TOM20	20
Nitrosative stress in Parkinson’s disease	20
Effect of Parkinson’s disease and two therapeutic interventions on muscle activity during walking: a systematic review	20
Reference SVA insertion polymorphisms are associated with Parkinson’s Disease progression and differential gene expression	20
Irritable bowel syndrome and Parkinson’s disease risk: register-based studies	19
Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson’s disease enrolled in PPMI	19
“Hot cross bun” is a potential imaging marker for the severity of cerebellar ataxia in MSA-C	19
Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors	19
Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology	19
Thalamic morphology predicts the onset of freezing of gait in Parkinson’s disease	19
The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson’s disease	19
Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages	18
Alpha-synuclein oligomers and small nerve fiber pathology in skin are potential biomarkers of Parkinson’s disease	18
A review on pathology, mechanism, and therapy for cerebellum and tremor in Parkinson’s disease	18
Pathways to Parkinson’s disease: a spotlight on 14-3-3 proteins	18
A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease	18
Post-GWAS knowledge gap: the how, where, and when	18
LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease	18
Insights into the multifaceted role of circular RNAs: implications for Parkinson’s disease pathogenesis and diagnosis	17
Distinct patterns of speech disorder in early-onset and late-onset de-novo Parkinson’s disease	17
Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America	17
Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson’s disease	16
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease	16
Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation	16
Comparative proteomic analysis highlights metabolic dysfunction in α-synucleinopathy	16
Akinetic rigid symptoms are associated with decline in a cortical motor network in Parkinson’s disease	16
A systematic review and meta-analysis of inflammatory biomarkers in Parkinson’s disease	16
Dynamic physiological α-synuclein S129 phosphorylation is driven by neuronal activity	16
A proteogenomic view of Parkinson’s disease causality and heterogeneity	15
Oral and gut dysbiosis leads to functional alterations in Parkinson’s disease	15
Exosome markers of LRRK2 kinase inhibition	15
Imaging mass cytometry reveals generalised deficiency in OXPHOS complexes in Parkinson’s disease	15
Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson’s disease	15
Predictors of clinically significant quality of life impairment in Parkinson’s disease	15
The CloudUPDRS smartphone software in Parkinson’s study: cross-validation against blinded human raters	15
Balance response to levodopa predicts balance improvement after bilateral subthalamic nucleus deep brain stimulation in Parkinson’s disease	15
Parkinson’s disease-associated, sex-specific changes in DNA methylation at PARK7 (DJ-1), SLC17A6 (VGLUT2), PTPRN2 (IA-2β), and NR4A2 (NURR1) in cortical neurons	14
A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD	14
Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase	14
Exploring human-genome gut-microbiome interaction in Parkinson’s disease	14
Mitophagy and reactive oxygen species interplay in Parkinson’s disease	14
Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson’s disease	14
Specific gut microbiota alterations in essential tremor and its difference from Parkinson’s disease	14
DAT and TH expression marks human Parkinson’s disease in peripheral immune cells	14
Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia	14
High neutrophil-to-lymphocyte ratio predicts short survival in multiple system atrophy	14
α-Synuclein-induced dysregulation of neuronal activity contributes to murine dopamine neuron vulnerability	14
Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinsons disease	14
Long-term Parkinson’s disease quality of life after staged DBS: STN vs GPi and first vs second lead	14
Glycation modulates glutamatergic signaling and exacerbates Parkinson’s disease-like phenotypes	14
Arm swing responsiveness to dopaminergic medication in Parkinson’s disease depends on task complexity	14
A series of helical α-synuclein fibril polymorphs are populated in the presence of lipid vesicles	14
Similarities and differences between nigral and enteric dopaminergic neurons unravel distinctive involvement in Parkinson’s disease	13
Improving estimation of Parkinson’s disease risk—the enhanced PREDICT-PD algorithm	13
A comparative study of asleep and awake deep brain stimulation robot-assisted surgery for Parkinson’s disease	13
Serum lipid profile among sporadic and familial forms of Parkinson’s disease	13
A systematic review and meta-analysis on effects of aerobic exercise in people with Parkinson’s disease	13
Adverse effects of hypertension, supine hypertension, and perivascular space on cognition and motor function in PD	13
Identification and prediction of Parkinson’s disease subtypes and progression using machine learning in two cohorts	13
Comprehensive subtyping of Parkinson’s disease patients with similarity fusion: a case study with BioFIND data	13
Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease	13
Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons	13
Probable REM sleep behavior disorder is associated with longitudinal cortical thinning in Parkinson’s disease	13
Parkinson’s disease patients benefit from bicycling - a systematic review and meta-analysis	13
Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US	13
Cholinesterase inhibitors for gait, balance, and fall in Parkinson disease: a meta-analysis	12
Altered interhemispheric synchrony in Parkinson’s disease patients with levodopa-induced dyskinesias	12
Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting	12
Cerebro-cerebellar motor networks in clinical subtypes of Parkinson’s disease	12
Shared genetic etiology between Parkinson’s disease and blood levels of specific lipids	12
Change in the incidence of Parkinson’s disease in a large UK primary care database	12
The effect of levodopa on bilateral coordination and gait asymmetry in Parkinson’s disease using inertial sensor	12
Association between inflammatory bowel disease and Parkinson’s disease: A Mendelian randomization study	12
Cdk5 phosphorylation-induced SIRT2 nuclear translocation promotes the death of dopaminergic neurons in Parkinson’s disease	12
Behavioural and neuroplastic effects of a double-blind randomised controlled balance exercise trial in people with Parkinson’s disease	12
Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity	12
Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis	12
Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease	12

Computer vision quantification of whole-body Parkinsonian bradykinesia using a large multi-site population	12
Axial impairment and falls in Parkinson’s disease: 15 years of subthalamic deep brain stimulation	12
Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study	12
Biallelic expansion in RFC1 as a rare cause of Parkinson’s disease	12
Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts	12
Multiomics implicate gut microbiota in altered lipid and energy metabolism in Parkinson’s disease	12
Melatonin ameliorates Parkinson’s disease via regulating microglia polarization in a RORα‐dependent pathway	11
A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinson’s disease	11
Self-reported periodontitis and C-reactive protein in Parkinson’s disease: a cross-sectional study of two American cohorts	11
Dysfunction in superior frontal gyrus associated with diphasic dyskinesia in Parkinson’s disease	11
Human moral decision-making through the lens of Parkinson’s disease	11
Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach	11
DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson’s disease	11
Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson’s disease patients	11
Impaired reach-to-grasp kinematics in parkinsonian patients relates to dopamine-dependent, subthalamic beta bursts	11
Parkinson’s disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration	11
Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease	10
Similar neuronal imprint and no cross-seeded fibrils in α-synuclein aggregates from MSA and Parkinson’s disease	10
White matter and nigral alterations in multiple system atrophy-parkinsonian type	10
Corneal nerve fiber loss relates to cognitive impairment in patients with Parkinson’s disease	10
Unlucky punches: the vulnerability-stress model for the development of impulse control disorders in Parkinson’s disease	10
Parkinson’s disease with restless legs syndrome—an in vivo corneal confocal microscopy study	10
Toward asleep DBS: cortico-basal ganglia spectral and coherence activity during interleaved propofol/ketamine sedation mimics NREM/REM sleep activity	10
Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease	10
Towards optimising experimental quantification of persistent pain in Parkinson’s disease using psychophysical testing	10
The emerging postural instability phenotype in idiopathic Parkinson disease	10
TNFα increases tyrosine hydroxylase expression in human monocytes	10
DBS-evoked cortical responses index optimal contact orientations and motor outcomes in Parkinson’s disease	10
Persistent dyskinesias in patients with fetal tissue transplantation for Parkinson disease	10
Delayed orthostatic hypotension in Parkinson’s disease	10
Deep nasal sinus cavity microbiota dysbiosis in Parkinson’s disease	9
Abnormal interhemispheric resting state functional connectivity in Parkinson’s disease patients with impulse control disorders	9
Mental health in people with Parkinson’s disease during the COVID-19 pandemic: potential for targeted interventions?	9
Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease	9
Genome-wide association study using whole-genome sequencing identifies risk loci for Parkinson’s disease in Chinese population	9
Functional connectivity in Parkinson’s disease candidates for deep brain stimulation	9
Glycolysis-enhancing α1-adrenergic antagonists modify cognitive symptoms related to Parkinson’s disease	9
A nationwide cohort study on diabetes severity and risk of Parkinson disease	9
The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism	9
Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson’s disease cohort	9
Fiber-specific white matter alterations in early-stage tremor-dominant Parkinson’s disease	9
Estrogen-related receptor gamma regulates mitochondrial and synaptic genes and modulates vulnerability to synucleinopathy	9
Restricted truncal sagittal movements of rapid eye movement behaviour disorder	9
Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson’s disease	9
Decreased frontotemporal connectivity in patients with parkinson’s disease experiencing face pareidolia	9
Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder	9
Longitudinal evolution of non-motor symptoms in early Parkinson’s disease: a 3-year prospective cohort study	9
Perspective on the current state of the LRRK2 field	9
Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson’s disease	9
Brain atrophy pattern in de novo Parkinson’s disease with probable RBD associated with cognitive impairment	8
Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy	8
Age at onset as stratifier in idiopathic Parkinson’s disease – effect of ageing and polygenic risk score on clinical phenotypes	8
C/EBPβ/AEP is age-dependently activated in Parkinson’s disease and mediates α-synuclein in the gut and brain	8
Cathepsin L-containing exosomes from α-synuclein-activated microglia induce neurotoxicity through the P2X7 receptor	8
Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool	8
Spatial lipidomics reveals brain region-specific changes of sulfatides in an experimental MPTP Parkinson’s disease primate model	8
Subthalamic deep brain stimulation improves sleep and excessive sweating in Parkinson’s disease	8
High content screening and proteomic analysis identify a kinase inhibitor that rescues pathological phenotypes in a patient-derived model of Parkinson’s disease	8
Parkinson-causing mutations in LRRK2 impair the physiological tetramerization of endogenous α-synuclein in human neurons	8
Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: A systematic review	8
Detecting Parkinson’s disease and its cognitive phenotypes via automated semantic analyses of action stories	8
An integrated biometric voice and facial features for early detection of Parkinson’s disease	8
Antagonistic network signature of motor function in Parkinson’s disease revealed by connectome-based predictive modeling	8
Neuroimaging signatures predicting motor improvement to focused ultrasound subthalamotomy in Parkinson’s disease	8
Pathophysiological evaluation of the LRRK2 G2385R risk variant for Parkinson’s disease	8
Il-10 signaling reduces survival in mouse models of synucleinopathy	8
Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkers	8
Redefining the hypotheses driving Parkinson’s diseases research	8
Case-control study of hypertension and Parkinson’s disease	8
Cardiac sympathetic burden reflects Parkinson disease burden, regardless of high or low orthostatic blood pressure changes	8
Combining skin and olfactory α-synuclein seed amplification assays (SAA)—towards biomarker-driven phenotyping in synucleinopathies	8
A non-invasive olfactory bulb measure dissociates Parkinson’s patients from healthy controls and discloses disease duration	7
Gut microbiota in dementia with Lewy bodies	7
Basal ganglia engagement during REM sleep movements in Parkinson’s disease	7
Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease	7
Gaps and roadmap of novel neuromodulation targets for treatment of gait in Parkinson’s disease	7
Association between Parkinson’s disease and the faecal eukaryotic microbiota	7
Druggable transcriptomic pathways revealed in Parkinson’s patient-derived midbrain neurons	7
Interdependence of metals and its binding proteins in Parkinson’s disease for diagnosis	7
Short-term effect of dopaminergic medication on speech in early-stage Parkinson’s disease	7
Clinical trajectories and biomarkers for weight variability in early Parkinson’s disease	7
A multicenter study of genetic testing for Parkinson’s disease in the clinical setting	7
Harmol promotes α-synuclein degradation and improves motor impairment in Parkinson’s models via regulating autophagy-lysosome pathway	7
Genetically engineered mesenchymal stem cells with dopamine synthesis for Parkinson’s disease in animal models	7
Thalamic white matter macrostructure and subnuclei volumes in Parkinson’s disease depression	7
Lateralized effects of deep brain stimulation in Parkinson’s disease: evidence and controversies	7
Dysautonomia and REM sleep behavior disorder contributions to progression of Parkinson’s disease phenotypes	7
Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus	7
Impaired migratory phenotype of CD4+ T cells in Parkinson’s disease	7
First delirium episode in Parkinson’s disease and parkinsonism: incidence, predictors, and outcomes	7
A randomized clinical trial of mindfulness meditation versus exercise in Parkinson’s disease during social unrest	6
Treadmill training in Parkinson’s disease is underpinned by the interregional connectivity in cortical-subcortical network	6
Pallidal stimulation as treatment for camptocormia in Parkinson’s disease	6
Speech acoustic indices for differential diagnosis between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy	6
Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein	6